WO2008086800A3 - Predisposition to, prognosis for and treatment of breast cancer relating to human chromosome 16 - Google Patents

Predisposition to, prognosis for and treatment of breast cancer relating to human chromosome 16 Download PDF

Info

Publication number
WO2008086800A3
WO2008086800A3 PCT/DK2008/000011 DK2008000011W WO2008086800A3 WO 2008086800 A3 WO2008086800 A3 WO 2008086800A3 DK 2008000011 W DK2008000011 W DK 2008000011W WO 2008086800 A3 WO2008086800 A3 WO 2008086800A3
Authority
WO
WIPO (PCT)
Prior art keywords
breast cancer
free
methods
predisposition
prognosis
Prior art date
Application number
PCT/DK2008/000011
Other languages
French (fr)
Other versions
WO2008086800A2 (en
Inventor
Lise Lotte Hansen
Jens Overgaard
Original Assignee
Univ Aarhus
Region Midtjylland
Lise Lotte Hansen
Jens Overgaard
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Aarhus, Region Midtjylland, Lise Lotte Hansen, Jens Overgaard filed Critical Univ Aarhus
Publication of WO2008086800A2 publication Critical patent/WO2008086800A2/en
Publication of WO2008086800A3 publication Critical patent/WO2008086800A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present invention relates to methods and kits based on the presence or absence of the c-mip gene located on the human chromosome 16, wherein reduced amounts of c-mip gene, transcriptional product, or translational product is indicative of a period of metastasis-free, recurrence-free and/or disease-free survival in an individual suffering from breast cancer. The invention, thus, relates to methods for the detection of predisposition to and/or for determining the prognosis for a period of metastasis-free, recurrence-free and/or disease-free survival of individuals suffering from breast cancer. Furthermore, the present invention pertains to a method for determining the treatment regime of an individual suffering from breast cancer as well as methods for classification of at least one tumour from an individual suffering from breast cancer. In addition, the invention pertains to kits for use in the methods.
PCT/DK2008/000011 2007-01-15 2008-01-15 Predisposition to, prognosis for and treatment of breast cancer relating to human chromosome 16 WO2008086800A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US88497507P 2007-01-15 2007-01-15
US60/884,975 2007-01-15
DKPA200700052 2007-01-15
DKPA200700052 2007-01-15

Publications (2)

Publication Number Publication Date
WO2008086800A2 WO2008086800A2 (en) 2008-07-24
WO2008086800A3 true WO2008086800A3 (en) 2008-09-04

Family

ID=39433866

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2008/000011 WO2008086800A2 (en) 2007-01-15 2008-01-15 Predisposition to, prognosis for and treatment of breast cancer relating to human chromosome 16

Country Status (1)

Country Link
WO (1) WO2008086800A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120083519A1 (en) * 2009-06-03 2012-04-05 Djillali Sahali Methods For Diagnosing And Treating A Renal Disease In An Individual
US20160040247A1 (en) * 2013-03-15 2016-02-11 Fundació Institut De Recerca Biomèdica (Irb Barcelona) Method for the diagnosis, prognosis, and tratment of cancer metastasis
MX2017007381A (en) 2014-12-11 2017-11-06 Inbiomotion Sl Binding members for human c-maf.

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5374533A (en) * 1988-05-10 1994-12-20 Tetjin Limited Method for determining chondrocalcin
WO2005005989A1 (en) * 2003-07-11 2005-01-20 F. Hoffmann-La Roche Ag A method for predicting the metastatic potential of breast cancer
WO2006052218A1 (en) * 2004-10-06 2006-05-18 Agency For Science, Technology And Research Methods, systems, and arrays based on correlating p53 status with gene expression profiles, for classification, prognosis, and diagnosis of cancers

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5374533A (en) * 1988-05-10 1994-12-20 Tetjin Limited Method for determining chondrocalcin
WO2005005989A1 (en) * 2003-07-11 2005-01-20 F. Hoffmann-La Roche Ag A method for predicting the metastatic potential of breast cancer
WO2006052218A1 (en) * 2004-10-06 2006-05-18 Agency For Science, Technology And Research Methods, systems, and arrays based on correlating p53 status with gene expression profiles, for classification, prognosis, and diagnosis of cancers

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
"Affymetrix - Show Tabled Results", INTERNET CITATION, 5 June 2008 (2008-06-05), pages 1 - 2, XP007904901, Retrieved from the Internet <URL:https://www.affymetrix.com/analysis/netaffx/showresults.affx> [retrieved on 20080605] *
DELOUKAS P ET AL: "A physical map of 30,000 human genes", SCIENCE, WASHINGTON, DC, vol. 282, no. 5389, 23 October 1998 (1998-10-23), pages 744 - 746, XP002213284, ISSN: 0036-8075 *
GRIMBERT PHILIPPE ET AL: "The Filamin-A is a partner of Tc-mip, a new adapter protein involved in c-maf-dependent Th2 signaling pathway.", MOLECULAR IMMUNOLOGY MAR 2004, vol. 40, no. 17, March 2004 (2004-03-01), pages 1257 - 1261, XP009101624, ISSN: 0161-5890 *
WANG ET AL: "Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer", LANCET THE, LANCET LIMITED. LONDON, GB, vol. 365, no. 9460, 19 February 2005 (2005-02-19), pages 671 - 679, XP005081323, ISSN: 0140-6736 *
YOON D S ET AL: "Genetic mapping and DNA sequence-based analysis of deleted regions on chromosome 16 involved in progression of bladder cancer from occult preneoplastic conditions to invasive disease", ONCOGENE, BASINGSTOKE, HANTS, GB, vol. 20, no. 36, 16 August 2001 (2001-08-16), pages 5005 - 5014, XP009101577, ISSN: 0950-9232 *

Also Published As

Publication number Publication date
WO2008086800A2 (en) 2008-07-24

Similar Documents

Publication Publication Date Title
Stamatopoulos et al. Opposite prognostic significance of cellular and serum circulating microRNA-150 in patients with chronic lymphocytic leukemia
NZ586834A (en) Methods of detecting signatures of disease or conditions in bodily fluids
WO2008146309A3 (en) Genetic variants on chr 5pl2 and 10q26 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
WO2009032974A3 (en) Nucleic acid-based methods for the detection of ovarian cancer
WO2010051314A3 (en) Genomic classification of non-small cell lung carcinoma based on patterns of gene copy number alterations
WO2007140958A3 (en) Method for identifying whether a patient will be responder or not to immunotherapy
WO2008030986A3 (en) Molecular diagnosis and classification of malignant melanoma
WO2008117314A3 (en) Genetic variants on chr2 and chr16 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
SG141418A1 (en) Method for the detection of gene transcripts in blood and uses thereof
WO2006089233A3 (en) Methods and systems for diagnosis, prognosis and selection of treatment of leukemia
WO2008028968A3 (en) Compounds regulating calreticulin, kdel receptor and/or erp-57 cell surface exposure and uses thereof to evaluate the efficiency of a cancer treatment
WO2007082099A3 (en) Gene expression markers for colorectal cancer prognosis
TW200600785A (en) Method for diagnosing non-small cell lung cancer
EP2392678A3 (en) Prognosis prediction for colorectal cancer
WO2010004591A3 (en) Genetic variants for breast cancer risk assessment
WO2011116088A3 (en) Compositions and methods for the detection of genomic features
WO2010033371A3 (en) Molecular markers for lung and colorectal carcinomas
WO2009024691A3 (en) Method of assaying leukocyte elastase inhibitor for the in vitro diagnosis of colorectal cancer
WO2005083429A8 (en) Breast cancer prognostics
WO2008057545A3 (en) Gene expression profiling based identification of genomic signatures of high-risk multiple myeloma and uses thereof
WO2009021054A3 (en) Novel single nucleotide polymorphisms and combinations of novel and known polymorphisms for determining the allele-specific expression of the igf2 gene
WO2011015944A3 (en) Use of free dna as an early predictor of severity in acute pancreatitis
SI1730315T1 (en) Polymorphisms in nod2/card15 gene
WO2009055823A3 (en) Method to predict responsiveness of breast cancer to polyaminetype chemotherapy
WO2008088860A3 (en) Polymorphisms in the egfr pathway as markers for cancer treatment

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08700883

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08700883

Country of ref document: EP

Kind code of ref document: A2